240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Financial Results, Costs of Shutting Down or Selling Parts of the Business
Shareholder votes
ORIC® Pharma's Preliminary Phase 1b Results of ORIC-944 Show Promise
Earnings Release
Annual Report to Security Holders
News, Material Contracts
Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities